A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

Astrazeneca's EVP – International shares how the company is working to deliver healthcare that is inclusive, impactful and ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

House Republicans are considering nixing a Medicaid drug-pricing plan floated by President Trump and fiercely opposed by ...

AstraZeneca, a globally leading biopharmaceutical company, kicked off construction on a new small molecule drug manufacturing ...

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

Shares of AstraZeneca PLC (AZN) traded 1% higher in pre-market on Friday after the company reported positive results from its ...

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...

Astrazeneca (AZN) closed the last trading session at $67.30, gaining 3.8% over the past four weeks, but there could be plenty ...